Division of Medical Oncology, Department of Precision Medicine, School of Medicine, "Luigi Vanvitelli" University of Campania, 80131 Naples, Italy.
Division of Medical Oncology, Department of Precision Medicine, School of Medicine, "Luigi Vanvitelli" University of Campania, 80131 Naples, Italy.
Cancer Treat Rev. 2019 Feb;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. Epub 2018 Dec 4.
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administrationand European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib. Furthermore, we anticipate the future perspective of combination regimens with antiangiogenic, immunocheckpoint inhibitors, and other biological agents as strategies to overcome resistance mechanisms, potentiate the therapeutic efficacy, and expand their clinical use in non-HR deficient tumors.
聚 ADP-核糖聚合酶抑制剂（PARPi）是目前批准用于治疗上皮性卵巢癌最有效和最有前景的治疗方法。它们改变了这种疾病的临床管理，这种疾病在几乎一半的病例中具有极端的遗传复杂性和 DNA 损伤修复途径的改变，特别是同源重组（HR）缺陷。在这篇综述中，我们提供了最近关于美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准的三种卵巢癌 PARPi（奥拉帕利、尼拉帕利和鲁卡帕利）的临床试验的最新结果的综述。此外，我们还预测了联合抗血管生成、免疫检查点抑制剂和其他生物制剂的治疗方案的未来前景，这些方案是克服耐药机制、增强治疗效果并扩大其在非 HR 缺陷肿瘤中的临床应用的策略。
Zotero 插件